EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer

Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents currently used to treat BRCA-mutant ovarian cancer and are in clinical trials for other cancer types, including BRCA-mutant breast cancer. To enhance the clinical response to PARP inhibitors (PARPi), understanding t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Hirohito, Du, Yi, Nakai, Katsuya, Ding, Ming, Chang, Shih-Shin, Hsu, Jennifer L., Yao, Jun, Wei, Yongkun, Nie, Lei, Jiao, Shiping, Chang, Wei-Chao, Chen, Chung-Hsuan, Yu, Yonghao, Hortobagyi, Gabriel N., Hung, Mien-Chie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786281/
https://www.ncbi.nlm.nih.gov/pubmed/28925391
http://dx.doi.org/10.1038/onc.2017.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786281/
https://www.ncbi.nlm.nih.gov/pubmed/28925391
http://dx.doi.org/10.1038/onc.2017.311

Ejemplares similares